A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants
Study Identifier:
ACH228-004
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ACH-0145228: Immediate Release
- Drug: ACH-0145228: Powder-in-capsule
Date
Jun 2020 - Oct 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ACH-0145228: Immediate Release
- Drug: ACH-0145228: Powder-in-capsule
Date
Jun 2020 - Oct 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information
Protocol Summary
This will be an open-label, 3-sequence, 3-period crossover study in healthy adult participants to assess the relative bioavailability of ACH-0145228 when administered as an immediate release tablet versus powder-in-capsule.
Trial Locations
Location
Status
Location
Clinical Trial Site
Lincoln, Nebraska, United States, 68502
Status
N/A